home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    DOCUMENTARIES LIFT LID ON THERANOS BIOTECH SCAM

    Jan 23, 2019

    As criminal fraud investigations continue into former Theranos CEO Elizabeth Holmes and president Ramesh Balwani, further details are emerging in two documentaries about how the company hoodwinked doctors, patients, and investors with bogus and exaggerated claims about its diagnostic technology. Ear...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24912491

    CRESCENT VISION DUAL-CAMERA HEADBAND FOR SURGEONS: CES 2019

    Jan 23, 2019

    Many surgical procedures are difficult to teach in practice because few people can gather around an operating table. Particularly with highly detailed surgeries, it is difficult to work on vessels and other anatomical structures while letting others have a good view of the scene as well. Crescent Te...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24922492

    ATTUNE PHARMACEUTICALS BAGS $23M FOR ORAL HAE DRUG

    Jan 23, 2019

    Attune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema (HAE) through phase 2. The biotech aims to provide an oral alternative to approved treatments, all of which are either intravenous or subcutaneous injections. The financing (PDF) comes one...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24932493

    CRISPR GENE EDITING STOCKS FALL AFTER EDITAS CEO RESIGNS

    Jan 23, 2019

    Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas. Massachusetts-based Editas said Katrine Bosley has decided to step down from her role as president and CEO, on March 1, 2019....


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24942494

    BIONTECH BUYS MAB DISCOVERY’S ANTIBODY GENERATION UNIT

    Jan 23, 2019

    BioNTech AG, located in Mainz, Germany, inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed. BioNTech will acquire all assets, employees and “proprietary know-how” for monoclonal ant...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24952495

    NICE BACKS DIGITAL CBT FOR YOUNGSTERS WITH DEPRESSION

    Jan 23, 2019

    NICE has recommended digital cognitive behavioural therapy (CBT) should be used as a first-line treatment for children and young people with mild depression. The draft guideline is an overarching document that paves the way for more use of this technology and is part of NICE’s drive to encoura...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24962496

    FDA PUTS TRANSLATE BIO’S RARE DISEASE MRNA DRUG ON HOLD

    Jan 23, 2019

    The FDA has placed a clinical hold on the IND for Translate Bio’s mRNA treatment for ornithine transcarbamylase (OTC) deficiency, a genetic disease that causes too much ammonia to build up in the blood. The hold comes just nine months after the agency lifted a clinical hold on a different prog...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24972497

    NEW REPORT SHOWS PRICE OF INSULIN DOUBLED FROM 2012 TO 2016

    Jan 23, 2019

    In October, Minnesota Attorney General Lori Swanson filed a lawsuit against three of the biggest insulin manufacturers over price gouging claims. In the lawsuit, Swanson said Eli Lilly, Sanofi and Novo Nordisk “deceptively raise the list price of insulin” and that the hikes have made the...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=24982498

TRENDING NEWS


    CATALYST DEFENDS HUGE US PRICE HIKE FOR RARE DISEASE DRUG

    Feb 22, 2019

    Catalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to more than $300,000 per year following criticism from Senator Bernie Sanders. Earlier this month Sanders, a vocal critic of big pharma’s pricing, wrote to Catalyst ...


    READ MORE

    https://pharmaphorum.com/news/catalyst-defends-huge-us-price-hike-for-rare-disease-drug/2631

    VOYAGER AND ABBVIE FORGE ANOTHER NEURODEGENERATIVE THERAPY COLLABORATION WORTH MORE THAN $1 BILLION

    Feb 22, 2019

    Voyager Therapeutics struck a deal with Illinois-based AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha...


    READ MORE

    https://www.biospace.com/article/voyager-and-abbvie-forge-another-neurodegenerative-therapy-collaboration-worth-more-than-1-billion/2632

    CELL THERAPY PRODUCES ENCOURAGING FIRST RESULTS IN EYE TRIAL

    Feb 22, 2019

    UK-based biotech ReNeuron has announced encouraging results from an early-stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP). The only results so far are from three subjects in the first cohort in phase 2 of a phase 1/2 trial of the disease. But this th...


    READ MORE

    https://pharmaphorum.com/news/reneuron-cell-therapy-produces-encouraging-results-in-early-eye-trial/2633

    ORCHARD EYES 2020 FOR FILING BLA FOR ADA-SCOD GENE THERAPY

    Feb 22, 2019

    Shares of Orchard Therapeutics are climbing this morning after the company announced positive results from a two-year follow up of the company’s stem cell gene therapy for the treatment of severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID). This morning the Lond...


    READ MORE

    https://www.biospace.com/article/orchard-eyes-2020-for-filing-bla-for-gene-therapy-for-ada-scod-an-inherited-immune-deficiency-disorder/2634

    FINAL NICE REJECTION FOR BIOMARIN’S CHILDHOOD RARE DISEASE DRUG

    Feb 22, 2019

    After a year of negotiations, NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease drug, saying that the company is unable to address concerns about long-term effectiveness. Brineura (cerliponase alfa) is designed to treat children with Batten disease, also known a...


    READ MORE

    https://pharmaphorum.com/news/final-nice-rejection-for-biomarins-childhood-rare-disease-drug/2635

    ALIMENTATION COUCHE-TARD AND CANOPY GROWTH JOIN FORCES TO LAUNCH A PREMIUM CANNABIS RETAIL BRAND IN LONDON, ONTARIO

    Feb 22, 2019

    Subsequent to this newly formed strategic partnership, and pending the results of a public consultation process, Alimentation Couche-Tard is excited to announce it has entered into a trademark license agreement with one of the winners of the Alcohol and Gaming Commission of Ontario's (the "...


    READ MORE

    https://www.biospace.com/article/releases/alimentation-couche-tard-and-canopy-growth-join-forces-to-launch-a-premium-cannabis-retail-brand-in-london-o2636

    COURT DOCUMENTS SHOW PURDUE’S RICHARD SACKLER DID NOT WANT TO CORRECT MISINFORMATION ABOUT STRENGTH OF OXYCONTIN

    Feb 22, 2019

    Court documents have shown how invested Richard Sackler was in the drive at Purdue Pharma to make OxyContin a success. A recent deposition that was unsealed has revealed just how far Sackler was willing to go to make that happen. STAT News, in concert with ProPublica, reported that Purdue executives...


    READ MORE

    https://www.biospace.com/article/court-documents-show-purdue-s-richard-sackler-did-not-want-to-correct-misinformation-about-the-strength-of-oxycontin/2637

    OPIANT’S MID-STAGE TREATMENT FOR A SEVERE EATING DISORDER FAILS TO REACH ENDPOINTS

    Feb 22, 2019

    Shares of Opiant Pharmaceuticals fell in trading Thursday and continue to slide in premarket trading this morning after the company announced its Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program. S...


    READ MORE

    https://www.biospace.com/article/opiant-s-mid-stage-treatment-for-a-severe-eating-disorder-fails-to-reach-endpoints/2638

    BAYER PAIRS ITS PRODUCTS IN FIRST-EVER TV AD FOR HORMONE-RELEASING IUDS

    Feb 22, 2019

    Bayer is taking on myths about intrauterine devices (IUDs) in a new two-product ad campaign. The first-ever campaign featuring both the Mirena and Kyleena branded IUDs recently began as Bayer looks to not only explain what the levonorgestrel-releasing IUDs do but also impart basic knowledge about IU...


    READ MORE

    https://www.fiercepharma.com/marketing/bayer-s-first-ever-tv-ad-for-two-its-hormone-releasing-iuds-driven-by-still-need-for2639

    HEALTH POLICY ANALYSTS CALL FOR MORE STRINGENT RULES FOR AI MEDICAL APPLICATIONS

    Feb 22, 2019

    A trio of health policy analysts from the University of Pennsylvania and the University of California has published a Policy Forum piece in the journal Science calling for more stringent rules for the introduction of AI medical applications. In their paper, Ravi Parikh, Ziad Obermeyer and Amol Navat...


    READ MORE

    https://medicalxpress.com/news/2019-02-health-policy-analysts-stringent-ai.html2640

    ABBVIE’S CANCER DRUG VENCLEXTA BLOCKS DIABETES IN MICE BY TARGETING BETA CELL ‘SENESCENCE’

    Feb 22, 2019

    Diabetes researchers have long believed that the disease starts when the immune system attacks insulin-producing beta cells in the pancreas. But that theory never made much sense to Anil Bhushan, Ph.D., a professor at the University of California, San Francisco, Diabetes Center. So he and a team of ...


    READ MORE

    https://www.fiercebiotech.com/biotech/abbvie-s-cancer-drug-venclexta-blocks-diabetes-mice-by-targeting-beta-cell-senescence2641

    PORTABLE, BATTERY POWERED VIRAL DETECTOR TAKES ONLY A DROP OF BLOOD

    Feb 22, 2019

    Performing a lab-quality test for many infectious diseases, particularly viral ones, is difficult in remote regions. Much lab equipment requires some kind of infrastructure, including clean rooms, trained staff, and money. Researchers at Purdue University have developed a device that can perform RNA...


    READ MORE

    https://www.medgadget.com/2019/02/portable-battery-powered-viral-detector-takes-only-a-drop-of-blood.html2642

    MENDELIAN GETS £500,000 FOR RARE DISEASE SCREENING TECH

    Feb 22, 2019

    UK health technology startup Mendelian has received a £500,000 grant from a government agency to build products that will help GPs identify patients with rare or hard to diagnose conditions and diseases. Mendelian will use the grant from Innovate UK to get a specialized screening system for ra...


    READ MORE

    https://pharmaphorum.com/news/mendelian-gets-500000-for-rare-disease-screening-tech/2643

    MARKET ACCESS ROUNDUP: UK HTA SHAKEUPS AS BREXIT FEARS DEEPEN

    Feb 22, 2019

    With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medical supplies that could follow a no-deal scenario. One government minister has said that a no-deal Brexit could disrupt medicines supplies to the UK for at least six months becaus...


    READ MORE

    https://pharmaphorum.com/views-and-analysis/market-access-roundup-uk-hta-shakeups-as-brexit-fears-deepen/2644

    J&J EARNS SPOT IN FORTUNE’S TOP 50 MOST RESPECTED COMPANIES

    Feb 21, 2019

    It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list. In life sciences and healthcare, Johnson & Johnson is a household name with trusted products that includes bandages, baby shampoos and so much mo...


    READ MORE

    https://www.biospace.com/article/j-and-j-earns-spot-in-fortune-s-top-50-most-respected-companies/2621

    MORE POSITIVE RESULTS FOR PFIZER/LILLY’S NON-OPIOID PAIN DRUG

    Feb 21, 2019

    Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP). In the study, treatment with tanezumab 10mg met the primary endpoint, demonstrating a statistically significant improvement in pain at ...


    READ MORE

    https://pharmaphorum.com/news/more-positive-results-for-pfizer-lillys-non-opioid-pain-drug/2622

SPOTLIGHT

ABC delivers a broad array of GLP and CGMP-compliant product development and analytical testing services to the pharmaceutical, biotech, animal health, crop protection, consumer products and chemical industries. This cross-industry, cross-regulatory experience adds value to the process of product de

RESOURCES

Events